PDF Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...

Fifty-two weeks after randomization, study drug administration was discontinued. To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug.

After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group. At two, four, and six months after the end of study drug administration, re-elevation of HbA1c was observed in all groups. Furthermore, in the tirzepatide groups, dose-dependent ...
Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...

Given a similar, if not superior, effectiveness for HbA1c reduction with additional weight reduction and no intrinsic risk of hypoglycemic episodes, GLP-1RAs are recommended as the preferred first ...
Effect on Hemoglobin A1c ( HbA1c ) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist ...

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...
To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug. Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group.
Fifty-two weeks after randomization, study drug administration was discontinued. To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug.

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...
TZP effectively lowers HbA1c and induces weight loss across its three doses for type 2 diabetes management, with increased adverse events observed at higher doses.
In individuals with obesity, discontinuation resulted in substantial increases in body weight , waist circumference, body mass index (BMI), systolic blood pressure, fasting plasma glucose, and HbA1c . Similar patterns were observed in type 2 diabetes, though fasting glucose rebound was less pronounced.

Impact on glycated haemoglobin and body weight changes after stopping ...
The duration of the off-drug treatment period was 4 weeks, which is not enough to affect HbA1c and body weight fully or determine the long-term effects of discontinuing tirzepatide treatment.







Repeated cycles of initiation, interruption and re-initiation of these drugs might induce body weight and HbA1c fluctuations — two risk factors for cardiovascular and microvascular events.